Ticker: JNJ | Published: 2026-09-21
Muted Trial Reaction
Johnson & Johnson is dipping moderately in quiet trading despite reporting positive late-stage clinical trial results for its psychiatric drug Caplyta, as investors show a muted reaction.
Sources: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHbr7tcNLZTJ8O1x0hC8zYe1z3AS73sLTuTcwdzKiAixhlSLG4dVN5RPllp0Ws-cN5JZL2rK45tjXnIZ7igSmuHJt75kjf